Open-Label, Randomized, Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Average Area Under the Plasma Concentration-time Curve to infinite time (AUCinfinity) of Glipizide After a Single Dose of Glipizide with Gastrointestinal Intubation and between Two Modified Release Glipizide formulations
研究概览
简要总结
In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study is to evaluate the in vivo drug dissolution and systemic absorption of modified release formulations of the BCS Class II drug Glipizide by direct sampling of stomach and small intestinal luminal content, blood, urine and feces.
Expanding current knowledge of drug dissolution in vivo will help to establish physiologically relevant in vitro models predictive of drug dissolution.
详细描述
This is an in vivo study designed to acquire human gastrointestinal (GI) physiology data from healthy subjects which are necessary for mechanistic absorption model development. Each subject will be asked to complete a single dosing phase. The dosing phase will include collection of fluids from stomach and gastrointestinal (GI) tract through intubation (putting a GI tube from mouth into stomach and intestines), blood, urine and feces, and measure glipizide concentrations.
The objectives of this study are, as follows: Objective #1: To characterize the plasma, gastrointestinal fluid, urine, and feces concentrations of glipizide after oral administration of modified release formulations; Objective #2: To compare the pharmacokinetics of glipizide between the two modified release formulations; Objective #3: To collect gastrointestinal physiology data in volunteers receiving an oral MR formulation of glipizide. These in vivo results will be used to validate in vitro dissolution methods and to support computational and mathematical modeling efforts, in order to develop an oral drug product optimization process that may be applied to future drugs to maximize oral drug safety and efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female adults age 18 to 55 years with BMI ranging from 18.5 to 35 kg/m2 inclusive
- •Ability to independently provide an informed consent
- •Demonstrate the ability to swallow a multivitamin pill that mimics a SmartPill capsule
- •Negative serum pregnancy test (for women of child-bearing potential)
排除标准
- •Unable to independently provide an informed consent for themselves or mentally incapacitated.
- •Physical disability (including blindness or deafness) that requires special arrangements.
- •Significant clinical illness, including cardiovascular disease, neurological disease, organ failure, or malignancy in the opinion of the investigator
- •Any surgical procedure within 3 weeks prior to screening
- •History and/or presence of severe seasonal allergies or severe allergic diseases including drug allergies, food allergies and allergy against the SmartPill® device
- •History and/or presence of hypersensitivity to any of the study drugs or the products' excipients
- •History and/or presence of hypersensitivity to Sulfonamide derivatives
- •History and/or presence of hypersensitivity to Lidocaine
- •History and/or presence of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of XIFAXAN
- •History and/or presence of hypersensitivity to acrylate or methacrylate, commonly used components of medical adhesives
- •Any other factor, condition, or disease, including, but not limited to, cardiovascular, respiratory, hematological, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient, alter drug absorption and pharmacokinetics or impact the validity of the study results.
- •Subjects with Type 1 Diabetes Mellitus (DM), diabetic ketoacidosis, with or without coma
- •Subjects with Glucose 6-phosphate dehydrogenase (G6PD) deficiency
- •History and/or presence of drug addiction or alcohol abuse within the past 12 months.
- •History of significant psychiatric or neurological illness, including seizure disorders.
- •Any medical or surgical conditions which might significantly interfere with the functions of gastrointestinal tract (e.g., gastric/intestinal bypass surgeries, fistulas, strictures, stenosis, or physiological/mechanical obstruction of the G.I tract, gastric bezoars, irritable bowel disease, crohn's disease, diverticulosis, or chronic narcotic use).
- •History of dysphagia to liquids, food, or pills
- •History of abdominal radiation therapy
- •Pregnant or lactating females
- •Any clinically significant abnormal lab values during screening in the opinion of the investigator.
- •Use of alcohol and/or nicotine containing products 48 hours prior to dosing visits, and throughout PK sampling visits.
- •Use of any medications and/or supplements, prescriptions or over the counter 1 week prior to beginning the study, and throughout the study except for birth control with approved methods of contraception when used consistently and correctly (Implants (i.e. Implanon, Nexplanon), Injectables (i.e. Depo-Provera), Combined, Oral Contraceptives, Intrauterine Devices (IUD's) (i.e. Mirena, ParaGard), and Sexual Abstinence are accepted).
- •Use of aspirin or any blood thinner medications.
- •Use of an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump.
- •Volunteers unwilling or unable to take the proposed drugs or undergo G.I intubation
- •Enrollment in a clinical trial in the past 30 days
- •Current enrollment in a clinical trial with another study drug, vaccine or medical device
- •Fasting blood glucose level < 80 mg/dL.
- •Inability or unwillingness to fast for 19 hours.
- •Blood donations in the past 8 weeks except for apheresis.
- •Volunteer shows a positive result of COVID-19 Antigen Rapid test in dosing visits
- •Volunteer is having any of the following symptoms:
- •Fever (over 100.4 oF or 38 oC) or feeling feverish
- •New cough
- •New shortness of breath
- •Volunteer is having two of any of these symptoms:
- •Muscle aches
- •New URI symptom(s) (runny nose, nasal congestion, and/or sore throat)
- •New loss of sense of smell or sense of taste
- •New headache
- •Volunteer has been in close contact in the last 14 days with someone recently diagnosed with COVID-19
- •Volunteer has returned from international travel within the past 10 days
研究组 & 干预措施
G.I Intubation
Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
干预措施: Glucotrol XL 5Mg Extended-Release Tablet (Drug)
G.I Intubation
Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
干预措施: Glipizide ER 5 MG 24 HR Extended Release Oral Tablet (Drug)
G.I Intubation
Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
干预措施: Rifaximin 200Mg Tab (Drug)
G.I Intubation
Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 20% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
干预措施: 13C6-Glipizide (Drug)
结局指标
主要结局
Average Area Under the Plasma Concentration-time Curve to infinite time (AUCinfinity) of Glipizide After a Single Dose of Glipizide with Gastrointestinal Intubation and between Two Modified Release Glipizide formulations
时间窗: From time 0 to 78 hours
Average Area Under the Plasma Concentration-time Curve to infinite time (AUCinfinity) of Glipizide will be measured at multiple timepoints over a 78 hour period at each of the two study phases
次要结局
- Plasma Cmax of Glipizide After a Single Dose of Glipizide with Gastrointestinal Intubation and between Two Modified Release Glipizide formulations(From time 0 to 78 hours)
- Plasma Tmax of Glipizide After a Single Dose of Glipizide with Gastrointestinal Intubation and between Two Modified Release Glipizide formulations(From time 0 to 78 hours)
- Urine and Feces concentrations of Glipizide After a Single Dose of Glipizide with Gastrointestinal Intubation and between Two Modified Release Glipizide formulations(From time 0 to 78 hours)
- Maximum Gastrointestinal fluid concentration of Glipizide after Oral Administration of a Single Dose Modified Released Formulation of Glipizide(From time 0 to 7 hours)
- Gastrointestinal pH after Oral Administration of Modified Release Formulation of Glipizide(From time 0 to 7 hours)
研究者
Duxin Sun
Charles R. Walgreen Jr. Professor of Pharmacy and Professor of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan
University of Michigan